{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T03:41:10Z","timestamp":1781235670993,"version":"3.54.1"},"reference-count":279,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T00:00:00Z","timestamp":1625788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system characterized by demyelination and axonal degeneration. MS patients typically present with a relapsing-remitting (RR) disease course, manifesting as sporadic attacks of neurological symptoms including ataxia, fatigue, and sensory impairment. While there are several effective disease-modifying therapies able to address the inflammatory relapses associated with RRMS, most patients will inevitably advance to a progressive disease course marked by a gradual and irreversible accrual of disabilities. Therapeutic intervention in progressive MS (PMS) suffers from a lack of well-characterized biological targets and, hence, a dearth of successful drugs. The few medications approved for the treatment of PMS are typically limited in their efficacy to<jats:italic>active<\/jats:italic>forms of the disease, have little impact on slowing degeneration, and fail to promote repair. In looking to address these unmet needs, the multifactorial therapeutic benefits of stem cell therapies are particularly compelling. Ostensibly providing neurotrophic support, immunomodulation and cell replacement, stem cell transplantation holds substantial promise in combatting the complex pathology of chronic neuroinflammation. Herein, we explore the current state of preclinical and clinical evidence supporting the use of stem cells in treating PMS and we discuss prospective hurdles impeding their translation into revolutionary regenerative medicines.<\/jats:p>","DOI":"10.3389\/fcell.2021.696434","type":"journal-article","created":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T10:14:04Z","timestamp":1625825644000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":47,"title":["Stem Cell Therapies for Progressive Multiple Sclerosis"],"prefix":"10.3389","volume":"9","author":[{"given":"Jayden A.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra M.","family":"Nicaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosana-Bristena","family":"Ionescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regan","family":"Hamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Peruzzotti-Jametti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Pluchino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1001\/jamaneurol.2019.2399","article-title":"Association of chronic active multiple sclerosis lesions with disability in vivo.","volume":"76","author":"Absinta","year":"2019","journal-title":"JAMA Neurol."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003145","article-title":"Neuroprotective effect of transplanted human embryonic stem cell-derived neural precursors in an animal model of multiple sclerosis.","volume":"3","author":"Aharonowiz","year":"2008","journal-title":"PLoS One"},{"key":"B3","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1146\/annurev-med-070119-115617","article-title":"Hematopoietic stem cell transplantation for autoimmune disease.","volume":"72","author":"Alexander","year":"2021","journal-title":"Annu. Rev. Med."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000021646","article-title":"The effect of stem cell therapy and comprehensive physical therapy in motor and non-motor symptoms in patients with multiple sclerosis: a comparative study.","volume":"99","author":"Alghwiri","year":"2020","journal-title":"Medicine"},{"key":"B5","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/nri1786","article-title":"Lymphoid neogenesis in chronic inflammatory diseases.","volume":"6","author":"Aloisi","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/2389753","article-title":"Allogeneic adipose-derived mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by regulating self-reactive T cell responses and dendritic cell function.","volume":"2017","author":"Anderson","year":"2017","journal-title":"Stem Cells Int."},{"key":"B7","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/ana.22054","article-title":"Meningeal T cells associate with diffuse axonal loss in multiple sclerosis spinal cords.","volume":"68","author":"Androdias","year":"2010","journal-title":"Ann. Neurol."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/srep40758","article-title":"Intraarterial route increases the risk of cerebral lesions after mesenchymal cell administration in animal model of ischemia.","volume":"7","author":"Argibay","year":"2017","journal-title":"Sci. Rep."},{"key":"B9","doi-asserted-by":"publisher","first-page":"508","DOI":"10.4161\/cib.3.6.13495","article-title":"Multifaceted regulation of T cells by CD44.","volume":"3","author":"Baaten","year":"2010","journal-title":"Commun. Integr. Biol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/nm1279","article-title":"Hyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation.","volume":"11","author":"Back","year":"2005","journal-title":"Nat. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/nn.3109","article-title":"Hepatocyte growth factor mediates mesenchymal stem cell\u2013induced recovery in multiple sclerosis models.","volume":"15","author":"Bai","year":"2012","journal-title":"Nat. Neurosci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1002\/glia.20841","article-title":"Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis.","volume":"57","author":"Bai","year":"2009","journal-title":"Glia"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-015-0272-1","article-title":"Hematopoietic stem cell transplantation for multiple sclerosis: is it a clinical reality?","volume":"7","author":"Bakhuraysah","year":"2016","journal-title":"Stem Cell Res. Ther."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21124407","article-title":"Transport of extracellular vesicles across the blood-brain barrier: brain pharmacokinetics and effects of inflammation.","volume":"21","author":"Banks","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/S1474-4422(06)70349-0","article-title":"The measurement and clinical relevance of brain atrophy in multiple sclerosis.","volume":"5","author":"Bermel","year":"2006","journal-title":"Lancet Neurol."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-018-0913-2","article-title":"Neural stem cell therapy for subacute and chronic ischemic stroke.","volume":"9","author":"Boese","year":"2018","journal-title":"Stem Cell Res. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e1215","DOI":"10.1212\/wnl.0000000000011461","article-title":"Long-term clinical outcomes of hematopoietic stem cell transplantation in multiple sclerosis.","volume":"96","author":"Boffa","year":"2021","journal-title":"Neurology"},{"key":"B18","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2174\/157488812804484648","article-title":"Autologous mesenchymal stem cell therapy in progressive multiple sclerosis: an open label study.","volume":"7","author":"Bonab","year":"2012","journal-title":"Curr. Stem Cell Res. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.stemcr.2015.01.001","article-title":"In vivo therapeutic potential of mesenchymal stromal cells depends on the source and the isolation procedure.","volume":"4","author":"Bortolotti","year":"2015","journal-title":"Stem Cell Rep."},{"key":"B20","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1038\/bmt.2011.208","article-title":"Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: long-term results.","volume":"47","author":"Bowen","year":"2012","journal-title":"Bone Marrow Transplant."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00455","article-title":"Use of stem cell extracellular vesicles as a \u201cholistic\u201d approach to CNS repair.","volume":"8","author":"Branscome","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1001\/jama.2018.20588","article-title":"Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis.","volume":"321","author":"Brown","year":"2019","journal-title":"JAMA"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2009.06.015","article-title":"The role of dendritic cells and regulatory T cells in the regulation of allergic asthma.","volume":"125","author":"Burchell","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1177\/1352458518805246","article-title":"Animal models of multiple sclerosis: from rodents to zebrafish.","volume":"25","author":"Burrows","year":"2019","journal-title":"Mult. Scler. J."},{"key":"B25","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/jama.2018.18743","article-title":"Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial.","volume":"321","author":"Burt","year":"2019","journal-title":"JAMA"},{"key":"B26","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1182\/blood.V91.7.2609","article-title":"Effect of disease stage on clinical outcome after syngeneic bone marrow transplantation for relapsing experimental autoimmune encephalomyelitis.","volume":"91","author":"Burt","year":"1998","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102404","article-title":"Health economics and patient outcomes of hematopoietic stem cell transplantation versus disease-modifying therapies for relapsing remitting multiple sclerosis in the United States of America.","volume":"45","author":"Burt","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"B28","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jneuroim.2006.05.003","article-title":"A role for CXCL12 (SDF-1alpha) in the pathogenesis of multiple sclerosis: regulation of CXCL12 expression in astrocytes by soluble myelin basic protein.","volume":"177","author":"Calderon","year":"2006","journal-title":"J. Neuroimmunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/ana.22109","article-title":"Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis.","volume":"69","author":"Campbell","year":"2011","journal-title":"Ann. Neurol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1126\/science.aan4183","article-title":"Defective cholesterol clearance limits remyelination in the aged central nervous system.","volume":"359","author":"Cantuti-Castelvetri","year":"2018","journal-title":"Science"},{"key":"B31","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.immuni.2011.06.011","article-title":"Leukemia inhibitory factor inhibits T helper 17 cell differentiation and confers treatment effects of neural progenitor cell therapy in autoimmune disease.","volume":"35","author":"Cao","year":"2011","journal-title":"Immunity"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-021-00498-5","article-title":"B cells in multiple sclerosis\u2014from targeted depletion to immune reconstitution therapies.","author":"Cencioni","year":"2021","journal-title":"Nat. Rev. Neurol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/glia.23733","article-title":"Stem cell derived oligodendrocytes to study myelin diseases.","volume":"68","author":"Chanoumidou","year":"2020","journal-title":"Glia"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1016\/S0140-6736(13)62242-4","article-title":"Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial.","volume":"383","author":"Chataway","year":"2014","journal-title":"Lancet"},{"key":"B35","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.stemcr.2014.04.005","article-title":"Human neural precursor cells promote neurologic recovery in a viral model of multiple sclerosis.","volume":"2","author":"Chen","year":"2014","journal-title":"Stem Cell Rep."},{"key":"B36","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.neulet.2009.02.024","article-title":"Transplantation of mesenchymal stem cells enhances axonal outgrowth and cell survival in an organotypic spinal cord slice culture.","volume":"454","author":"Cho","year":"2009","journal-title":"Neurosci. Lett."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1093\/brain\/aws189","article-title":"Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis.","author":"Choi","year":"2012","journal-title":"Brain"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/cells8121497","article-title":"Placental mesenchymal stem cell-derived extracellular vesicles promote myelin regeneration in an animal model of multiple sclerosis.","volume":"8","author":"Clark","year":"2019","journal-title":"Cells"},{"key":"B39","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1177\/1352458517703802","article-title":"Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.","volume":"24","author":"Cohen","year":"2018","journal-title":"Mult. Scler."},{"key":"B40","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/b978-0-444-52001-2.00014-5","article-title":"The clinical course of multiple sclerosis.","volume":"122","author":"Confavreux","year":"2014","journal-title":"Handb. Clin. Neurol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/s1474-4422(11)70305-2","article-title":"Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study.","volume":"11","author":"Connick","year":"2012","journal-title":"Lancet Neurol."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-12-62","article-title":"The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments.","volume":"12","author":"Connick","year":"2011","journal-title":"Trials"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1002\/stem.194","article-title":"Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis.","volume":"27","author":"Constantin","year":"2009","journal-title":"Stem Cells"},{"key":"B44","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1146\/annurev-pathol-121808-102144","article-title":"The senescence-associated secretory phenotype: the dark side of tumor suppression.","volume":"5","author":"Coppe","year":"2010","journal-title":"Annu. Rev. Pathol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1182\/blood-2005-07-2657","article-title":"Human mesenchymal stem cells modulate B-cell functions.","volume":"107","author":"Corcione","year":"2006","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00441-012-1341-8","article-title":"New perspectives of tissue remodelling with neural stem and progenitor cell-based therapies.","volume":"349","author":"Cossetti","year":"2012","journal-title":"Cell Tissue Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.molcel.2014.08.020","article-title":"Extracellular vesicles from neural stem cells transfer IFN-gamma via Ifngr1 to activate Stat1 signaling in target cells.","volume":"56","author":"Cossetti","year":"2014","journal-title":"Mol. Cell"},{"key":"B48","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1136\/jnnp-2020-324286","article-title":"Systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis.","volume":"92","author":"Cunniffe","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B49","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1093\/brain\/awr339","article-title":"Transplanted neural stem\/precursor cells instruct phagocytes and reduce secondary tissue damage in the injured spinal cord.","author":"Cusimano","year":"2012","journal-title":"Brain"},{"key":"B50","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.omtn.2018.12.009","article-title":"Generation of genetically stable human direct-conversion-derived neural stem cells using quantity control of proto-oncogene expression.","volume":"14","author":"Daekee","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B51","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/cns.12759","article-title":"Mesenchymal stem cells and conditioned media in the treatment of multiple sclerosis patients: clinical, ophthalmological and radiological assessments of safety and efficacy.","volume":"23","author":"Dahbour","year":"2017","journal-title":"CNS Neurosci. Ther."},{"key":"B52","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s11899-019-00505-z","article-title":"Autologous haematopoietic stem cell transplantation in multiple sclerosis: a review of current literature and future directions for transplant haematologists and oncologists.","volume":"14","author":"Das","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"B53","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.1172\/JCI92387","article-title":"Neural precursor cell-secreted TGF-\u03b22 redirects inflammatory monocyte-derived cells in CNS autoimmunity.","volume":"127","author":"De Feo","year":"2017","journal-title":"J. Clin. Invest."},{"key":"B54","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/brain\/124.8.1635","article-title":"Post-mortem MRI-guided sampling of multiple sclerosis brain lesions: increased yield of active demyelinating and (p)reactive lesions.","author":"De Groot","year":"2001","journal-title":"Brain"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/srep16795","article-title":"Intravenous multipotent adult progenitor cell treatment decreases inflammation leading to functional recovery following spinal cord injury.","volume":"5","author":"DePaul","year":"2015","journal-title":"Sci. Rep."},{"key":"B56","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/s1474-4422(19)30391-6","article-title":"Advances in oral immunomodulating therapies in relapsing multiple sclerosis.","volume":"19","author":"Derfuss","year":"2020","journal-title":"Lancet Neurol."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21197336","article-title":"Emerging role of extracellular vesicles in the pathophysiology of multiple sclerosis.","volume":"21","author":"Dolcetti","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3791\/51154","article-title":"Systemic injection of neural stem\/progenitor cells in mice with chronic EAE.","volume":"86","author":"Donega","year":"2014","journal-title":"J. Vis. Exp."},{"key":"B59","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/s41593-021-00801-z","article-title":"Oxidized phosphatidylcholines found in multiple sclerosis lesions mediate neurodegeneration and are neutralized by microglia.","volume":"24","author":"Dong","year":"2021","journal-title":"Nat. Neurosci."},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-016-0667-7","article-title":"Metabolic determinants of the immune modulatory function of neural stem cells.","volume":"13","author":"Drago","year":"2016","journal-title":"J. Neuroinflammation"},{"key":"B61","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1016\/j.biochi.2013.06.020","article-title":"The stem cell secretome and its role in brain repair.","volume":"95","author":"Drago","year":"2013","journal-title":"Biochimie"},{"key":"B62","first-page":"24","article-title":"Mesenchymal stem cells in multiple sclerosis\u2013translation to clinical trials.","volume":"8","author":"Dulamea","year":"2015","journal-title":"J. Med. Life"},{"key":"B63","doi-asserted-by":"publisher","first-page":"5257","DOI":"10.1007\/s11033-019-04983-5","article-title":"Human intracerebroventricular (ICV) injection of autologous, non-engineered, adipose-derived stromal vascular fraction (ADSVF) for neurodegenerative disorders: results of a 3-year phase 1 study of 113 injections in 31 patients.","volume":"46","author":"Duma","year":"2019","journal-title":"Mol. Biol. Rep."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pneurobio.2010.09.005","article-title":"Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis.","volume":"93","author":"Dutta","year":"2011","journal-title":"Prog. Neurobiol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/ana.21033","article-title":"Neural precursors attenuate autoimmune encephalomyelitis by peripheral immunosuppression.","volume":"61","author":"Einstein","year":"2007","journal-title":"Ann. Neurol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1002\/1873-3468.13656","article-title":"Take the shortcut\u2013direct conversion of somatic cells into induced neural stem cells and their biomedical applications.","volume":"593","author":"Erharter","year":"2019","journal-title":"FEBS Lett."},{"key":"B67","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.mcn.2008.07.007","article-title":"Neural precursor cells inhibit multiple inflammatory signals.","volume":"39","author":"Fainstein","year":"2008","journal-title":"Mol. Cell Neurosci."},{"key":"B68","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/s41573-019-0035-2","article-title":"Progressive multiple sclerosis: from pathophysiology to therapeutic strategies.","volume":"18","author":"Faissner","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"B69","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/sj.bmt.1700944","article-title":"Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study.","volume":"20","author":"Fassas","year":"1997","journal-title":"Bone Marrow Transplant."},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1177\/2055217319856035","article-title":"Exploratory MRI measures after intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.","volume":"5","author":"Feng","year":"2019","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195891","article-title":"Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: a triple blinded, placebo controlled, randomized phase I\/II safety and feasibility study.","volume":"13","author":"Fernandez","year":"2018","journal-title":"PLoS ONE"},{"key":"B72","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1089\/scd.2008.0253","article-title":"Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect.","volume":"18","author":"Fischer","year":"2009","journal-title":"Stem Cells Dev."},{"key":"B73","doi-asserted-by":"publisher","first-page":"709","DOI":"10.2217\/rme.14.63","article-title":"Generating induced pluripotent stem cells for multiple sclerosis therapy.","volume":"9","author":"Fossati","year":"2014","journal-title":"Regen. Med."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1177\/1352458512458169","article-title":"Setting a research agenda for progressive multiple sclerosis: The International Collaborative on Progressive MS.","volume":"18","author":"Fox","year":"2012","journal-title":"Mult. Scler."},{"key":"B75","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/nrn2480","article-title":"Remyelination in the CNS: from biology to therapy.","volume":"9","author":"Franklin","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"key":"B76","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/nrn.2017.136","article-title":"Regenerating CNS myelin - from mechanisms to experimental medicines.","volume":"18","author":"Franklin","year":"2017","journal-title":"Nat. Rev. Neurosci."},{"key":"B77","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1177\/1352458509359727","article-title":"The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group.","volume":"16","author":"Freedman","year":"2010","journal-title":"Mult. Scler. J."},{"key":"B78","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/nrneurol.2014.37","article-title":"Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis.","volume":"10","author":"Friese","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1093\/brain\/awp070","article-title":"The relation between inflammation and neurodegeneration in multiple sclerosis brains.","author":"Frischer","year":"2009","journal-title":"Brain"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.327","article-title":"Mesenchymal stem cells and immunomodulation: current status and future prospects.","volume":"7","author":"Gao","year":"2016","journal-title":"Cell Death Dis."},{"key":"B81","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.scr.2017.07.015","article-title":"Neurotrophy and immunomodulation of induced neural stem cell grafts in a mouse model of closed head injury.","volume":"23","author":"Gao","year":"2017","journal-title":"Stem Cell Res."},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/5840286","article-title":"Autologous hematopoietic cell transplantation in multiple sclerosis: changing paradigms in the era of novel agents.","volume":"2019","author":"Gavriilaki","year":"2019","journal-title":"Stem Cells Int."},{"key":"B83","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/ana.21076","article-title":"Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis.","volume":"61","author":"Gerdoni","year":"2007","journal-title":"Ann. Neurol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1111\/j.1476-5381.2012.02061.x","article-title":"The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate.","volume":"167","author":"Gergely","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jneuroim.2004.02.012","article-title":"TNFR1-dependent VCAM-1 expression by astrocytes exposes the CNS to destructive inflammation.","volume":"151","author":"Gimenez","year":"2004","journal-title":"J. Neuroimmunol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1182\/blood-2004-09-3696","article-title":"Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells.","volume":"105","author":"Glennie","year":"2005","journal-title":"Blood"},{"key":"B87","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/(SICI)1097-4547(19990701)57:1<74::AID-JNR8<3.0.CO;2-O","article-title":"In vivo actions of fibroblast growth factor-2 and insulin-like growth factor-I on oligodendrocyte development and myelination in the central nervous system.","volume":"57","author":"Goddard","year":"1999","journal-title":"J. Neurosci. Res."},{"key":"B88","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jns.2013.02.011","article-title":"Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy.","volume":"328","author":"Groves","year":"2013","journal-title":"J. Neurol. Sci."},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21228662","article-title":"Mesenchymal stem cells in multiple sclerosis: recent evidence from pre-clinical to clinical studies.","volume":"21","author":"Gugliandolo","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B90","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1159\/000351450","article-title":"Human mesenchymal stem cells upregulate CD1dhighCD5+ regulatory B cells in experimental autoimmune encephalomyelitis.","volume":"20","author":"Guo","year":"2013","journal-title":"Neuroimmunomodulation"},{"key":"B91","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1093\/brain\/awv398","article-title":"The topograpy of demyelination and neurodegeneration in the multiple sclerosis brain.","author":"Haider","year":"2016","journal-title":"Brain"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8838046","article-title":"Mesenchymal stem\/stromal cell-mediated mitochondrial transfer and the therapeutic potential in treatment of neurological diseases.","volume":"2020","author":"Han","year":"2020","journal-title":"Stem Cells Int."},{"key":"B93","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.stem.2012.02.021","article-title":"Direct reprogramming of fibroblasts into neural stem cells by defined factors.","volume":"10","author":"Han, Dong","year":"2012","journal-title":"Cell Stem Cell"},{"key":"B94","doi-asserted-by":"publisher","first-page":"536","DOI":"10.5966\/sctm.2012-0015","article-title":"Characterization of autologous mesenchymal stem cell-derived neural progenitors as a feasible source of stem cells for central nervous system applications in multiple sclerosis.","volume":"1","author":"Harris","year":"2012","journal-title":"Stem Cells Transl. Med."},{"key":"B95","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ebiom.2018.02.002","article-title":"Phase I trial of intrathecal mesenchymal stem cell-derived neural progenitors in progressive multiple sclerosis.","volume":"29","author":"Harris","year":"2018","journal-title":"EBioMedicine"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000928","article-title":"Mesenchymal stem cell-derived neural progenitors in progressive MS: two-year follow-up of a phase I study.","volume":"8","author":"Harris","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.jcyt.2016.08.007","article-title":"Clinical safety of intrathecal administration of mesenchymal stromal cell-derived neural progenitors in multiple sclerosis.","volume":"18","author":"Harris","year":"2016","journal-title":"Cytotherapy"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2017.00028","article-title":"Mesenchymal stem cells in the treatment of traumatic brain injury.","volume":"8","author":"Hasan","year":"2017","journal-title":"Front. Neurol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.","volume":"358","author":"Hauser","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"B100","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/ana.21867","article-title":"Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.","volume":"66","author":"Hawker","year":"2009","journal-title":"Ann. Neurol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.stemcr.2014.06.017","article-title":"Induced neural stem cells achieve long-term survival and functional integration in the adult mouse brain.","volume":"3","author":"Hemmer","year":"2014","journal-title":"Stem Cell Rep."},{"key":"B102","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.scr.2009.02.002","article-title":"Teratoma formation by human embryonic stem cells: evaluation of essential parameters for future safety studies.","volume":"2","author":"Hentze","year":"2009","journal-title":"Stem Cell Res."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1182\/blood-2004-12-4607","article-title":"Tolerance induction by bone marrow transplantation in a multiple sclerosis model.","volume":"106","author":"Herrmann","year":"2005","journal-title":"Blood"},{"key":"B104","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1097\/01.jnen.0000235119.52311.16","article-title":"Dysferlin is a new marker for leaky brain blood vessels in multiple sclerosis.","volume":"65","author":"Hochmeister","year":"2006","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1046\/j.1365-2990.2003.00491.x","article-title":"Astrocyte characterization in the multiple sclerosis glial scar.","volume":"29","author":"Holley","year":"2003","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jconrel.2019.02.032","article-title":"Immunomodulatory properties of MSC-derived exosomes armed with high affinity aptamer toward mylein as a platform for reducing multiple sclerosis clinical score.","volume":"299","author":"Hosseini Shamili","year":"2019","journal-title":"J. Control. Release"},{"key":"B107","doi-asserted-by":"publisher","first-page":"404","DOI":"10.4161\/cam.26941","article-title":"Transplantation of umbilical cord and bone marrow-derived mesenchymal stem cells in a patient with relapsing-remitting multiple sclerosis.","volume":"7","author":"Hou","year":"2013","journal-title":"Cell Adh. Migr."},{"key":"B108","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1093\/brain\/awr182","article-title":"Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis.","author":"Howell","year":"2011","journal-title":"Brain"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.526","article-title":"Mesenchymal stem cell-based treatments for stroke, neural trauma, and heat stroke.","volume":"6","author":"Hsuan","year":"2016","journal-title":"Brain Behav."},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01526-w","article-title":"Failed, interrupted, or inconclusive trials on neuroprotective and neuroregenerative treatment strategies in multiple sclerosis: update 2015\u20132020.","author":"Huntemann","year":"2021","journal-title":"Drugs"},{"key":"B111","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/mus.23920","article-title":"Inflammatory hypertrophic cauda equina following intrathecal neural stem cell injection.","volume":"48","author":"Hurst","year":"2013","journal-title":"Muscle Nerve"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8122102","article-title":"Short and long term clinical and immunologic follow up after bone marrow mesenchymal stromal cell therapy in progressive multiple sclerosis-A phase I study.","volume":"8","author":"Iacobaeus","year":"2019","journal-title":"J. Clin. Med."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1007\/s00415-019-09489-5","article-title":"A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition.","volume":"268","author":"Inojosa","year":"2019","journal-title":"J. Neurol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/nchembio.2422","article-title":"Extracellular vesicles are independent metabolic units with asparaginase activity.","volume":"13","author":"Iraci","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"8779","DOI":"10.1002\/jcp.29721","article-title":"Therapeutic effects of extracellular vesicles from human adipose-derived mesenchymal stem cells on chronic experimental autoimmune encephalomyelitis.","volume":"235","author":"Jafarinia","year":"2020","journal-title":"J. Cell. Physiol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41586-019-0903-2","article-title":"Altered human oligodendrocyte heterogeneity in multiple sclerosis.","volume":"566","author":"J\u00e4kel","year":"2019","journal-title":"Nature"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2017.00317","article-title":"Perspective insights of exosomes in neurodegenerative diseases: a critical appraisal.","volume":"9","author":"Jan","year":"2017","journal-title":"Front. Aging Neurosci."},{"key":"B118","doi-asserted-by":"publisher","first-page":"9794","DOI":"10.1523\/JNEUROSCI.2116-06.2006","article-title":"Protecting axonal degeneration by increasing nicotinamide adenine dinucleotide levels in experimental autoimmune encephalomyelitis models.","volume":"26","author":"Kaneko","year":"2006","journal-title":"J. Neurosci."},{"key":"B119","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1474-4422(18)30069-3","article-title":"Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.","volume":"17","author":"Kapoor","year":"2018","journal-title":"Lancet Neurol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet"},{"key":"B121","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1001\/archneurol.2010.248","article-title":"Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis.","volume":"67","author":"Karussis","year":"2010","journal-title":"Arch. Neurol."},{"key":"B122","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.4049\/jimmunol.148.6.1693","article-title":"Prevention of experimental autoimmune encephalomyelitis and induction of tolerance with acute immunosuppression followed by syngeneic bone marrow transplantation.","volume":"148","author":"Karussis","year":"1992","journal-title":"J. Immunol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1172\/jci116648","article-title":"Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation.","volume":"92","author":"Karussis","year":"1993","journal-title":"J. Clin. Invest."},{"key":"B124","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1089\/neu.2008.0818","article-title":"Therapeutic effects of human mesenchymal stem cells on traumatic brain injury in rats: secretion of neurotrophic factors and inhibition of apoptosis.","volume":"27","author":"Kim","year":"2010","journal-title":"J. Neurotrauma"},{"key":"B125","doi-asserted-by":"publisher","first-page":"7838","DOI":"10.1073\/pnas.1103113108","article-title":"Direct reprogramming of mouse fibroblasts to neural progenitors.","volume":"108","author":"Kim","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B126","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/ana.25592","article-title":"Telomere length is associated with disability progression in multiple sclerosis.","volume":"86","author":"Krysko","year":"2019","journal-title":"Ann. Neurol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1093\/brain\/awh641","article-title":"Cortical demyelination and diffuse white matter injury in multiple sclerosis.","author":"Kutzelnigg","year":"2005","journal-title":"Brain"},{"key":"B128","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1136\/jnnp-2012-303291","article-title":"Interferon beta for secondary progressive multiple sclerosis: a systematic review.","volume":"84","author":"La Mantia","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0202590","article-title":"Therapeutic potential of extracellular vesicles derived from human mesenchymal stem cells in a model of progressive multiple sclerosis.","volume":"13","author":"Laso-Garc\u00eda","year":"2018","journal-title":"PLoS One"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.03116","article-title":"Pathogenic mechanisms associated with different clinical courses of multiple sclerosis.","volume":"9","author":"Lassmann","year":"2018","journal-title":"Front. Immunol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/nrneurol.2012.168","article-title":"Progressive multiple sclerosis: pathology and pathogenesis.","volume":"8","author":"Lassmann","year":"2012","journal-title":"Nat. Rev. Neurol."},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3597","article-title":"iPSC-derived neural precursors exert a neuroprotective role in immune-mediated demyelination via the secretion of LIF.","volume":"4","author":"Laterza","year":"2013","journal-title":"Nat. Commun."},{"key":"B133","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1212\/WNL.60.1.44","article-title":"Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.","volume":"60","author":"Leary","year":"2003","journal-title":"Neurology"},{"key":"B134","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/nm.3267","article-title":"Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies.","volume":"19","author":"Lee","year":"2013","journal-title":"Nat. Med."},{"key":"B135","doi-asserted-by":"publisher","first-page":"S113","DOI":"10.3727\/096368914x685005","article-title":"The potential of human umbilical cord-derived mesenchymal stem cells as a novel cellular therapy for multiple sclerosis.","author":"Li","year":"2014","journal-title":"Cell Transplant."},{"key":"B136","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.yexmp.2015.01.016","article-title":"Intranasal delivery of stem cells as therapy for central nervous system disease.","volume":"98","author":"Li","year":"2015","journal-title":"Exp. Mol. Pathol."},{"key":"B137","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.intimp.2018.12.001","article-title":"Exosomes derived from mesenchymal stem cells attenuate inflammation and demyelination of the central nervous system in EAE rats by regulating the polarization of microglia.","volume":"67","author":"Li","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0113936","article-title":"Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis.","volume":"9","author":"Llufriu","year":"2014","journal-title":"PLoS One"},{"key":"B139","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.cell.2013.05.039","article-title":"The hallmarks of aging.","volume":"153","author":"L\u00f3pez-Ot\u00edn","year":"2013","journal-title":"Cell"},{"key":"B140","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1001\/archneurol.2010.117","article-title":"Neuroinflammation and demyelination in multiple sclerosis after allogeneic hematopoietic stem cell transplantation.","volume":"67","author":"Lu","year":"2010","journal-title":"Arch. Neurol."},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.4172\/2157-7633.S6-002","article-title":"Human umbilical cord mesenchymal stem cells in the treatment of secondary progressive multiple sclerosis.","author":"Lu","year":"2013","journal-title":"J. Stem Cell Res. Ther."},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00967","article-title":"IV\/IT hUC-MSCs infusion in RRMS and NMO: a 10-year follow-up study.","volume":"11","author":"Lu","year":"2020","journal-title":"Front. Neurol."},{"key":"B143","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.msard.2014.08.002","article-title":"Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study.","volume":"3","author":"Lublin","year":"2014","journal-title":"Mult. Scler. Relat. Disord."},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2019.112458","article-title":"Adult neurogenesis, human after all (again): classic, optimized, and future approaches.","volume":"381","author":"Lucassen","year":"2020","journal-title":"Behav. Brain Res."},{"key":"B145","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1073\/pnas.1121003109","article-title":"Direct conversion of mouse fibroblasts to self-renewing, tripotent neural precursor cells.","volume":"109","author":"Lujan","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B146","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1017\/S0317167100047922","article-title":"Nuclear magnetic resonance study of cerebrospinal fluid from patients with multiple sclerosis.","volume":"20","author":"Lynch","year":"1993","journal-title":"Can. J. Neurol. Sci."},{"key":"B147","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1093\/brain\/awm038","article-title":"Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology.","author":"Magliozzi","year":"2007","journal-title":"Brain"},{"key":"B148","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/NEN.0b013e31827bfc62","article-title":"B-cell enrichment and Epstein-Barr virus infection in inflammatory cortical lesions in secondary progressive multiple sclerosis.","volume":"72","author":"Magliozzi","year":"2013","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"B149","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pneurobio.2015.02.003","article-title":"The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis.","author":"Mallucci","year":"2015","journal-title":"Prog. Neurobiol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1056\/NEJMoa1608368","article-title":"Autologous induced stem-cell-derived retinal cells for macular degeneration.","volume":"376","author":"Mandai","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.116830","article-title":"The potential use of mesenchymal stem cells for the treatment of multiple sclerosis.","volume":"235","author":"Mansoor","year":"2019","journal-title":"Life Sci."},{"key":"B152","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.neuint.2017.02.006","article-title":"Neural stem cell therapy for neurodegenerative disorders: the role of neurotrophic support.","volume":"106","author":"Marsh","year":"2017","journal-title":"Neurochem. Int."},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat2189","article-title":"Challenges for mesenchymal stromal cell therapies.","volume":"11","author":"Martin","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002127.pub3","article-title":"Mitoxantrone for multiple sclerosis.","author":"Martinelli Boneschi","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"B155","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/nrn1908","article-title":"The therapeutic potential of neural stem cells.","volume":"7","author":"Martino","year":"2006","journal-title":"Nat. Rev. Neurosci."},{"key":"B156","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/nm.3681","article-title":"Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation.","volume":"20","author":"Mayo","year":"2014","journal-title":"Nat. Med."},{"key":"B157","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/sj.bmt.1700666","article-title":"Allogeneic bone marrow transplant for chronic myelogenous leukemia in a patient with multiple sclerosis.","volume":"19","author":"McAllister","year":"1997","journal-title":"Bone Marrow Transplant."},{"key":"B158","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3233\/rnn-2011-0590","article-title":"Treatment of an autoimmune encephalomyelitis mouse model with nonmyeloablative conditioning and syngeneic bone marrow transplantation.","volume":"29","author":"Meng","year":"2011","journal-title":"Restor. Neurol. Neurosci."},{"key":"B159","first-page":"212","article-title":"Umbilical cord mesenchymal stem cell transplantation in the treatment of multiple sclerosis.","volume":"10","author":"Meng","year":"2018","journal-title":"Am. J. Transl. Res."},{"key":"B160","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1001\/jamaneurol.2020.4025","article-title":"Autologous hematopoietic stem cell transplant in multiple sclerosis: recommendations of the national multiple sclerosis society.","volume":"78","author":"Miller","year":"2021","journal-title":"JAMA Neurol."},{"key":"B161","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1191\/1352458503ms965oa","article-title":"Blood-brain barrier disruption in multiple sclerosis.","volume":"9","author":"Minagar","year":"2003","journal-title":"Mult. Scler. J."},{"key":"B162","first-page":"50","article-title":"Does mesenchymal stem cell therapy help multiple sclerosis patients? Report of a pilot study.","volume":"4","author":"Mohyeddin Bonab","year":"2007","journal-title":"Iran. J. Immunol."},{"key":"B163","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis.","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B164","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/s12975-011-0095-z","article-title":"Intracranial delivery of stem cells.","volume":"2","author":"Muir","year":"2011","journal-title":"Trans. Stroke Res."},{"key":"B165","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nrneurol.2017.81","article-title":"Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis.","volume":"13","author":"Muraro","year":"","journal-title":"Nat. Rev. Neurol."},{"key":"B166","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1001\/jamaneurol.2016.5867","article-title":"Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis.","volume":"74","author":"Muraro","year":"","journal-title":"JAMA Neurol."},{"key":"B167","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1002\/sctm.16-0438","article-title":"Feasibility and efficacy of intra-arterial administration of mesenchymal stem cells in an animal model of double toxin-induced multiple system atrophy.","volume":"6","author":"Na Kim","year":"2017","journal-title":"Stem Cells Transl. Med."},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1186\/s41232-020-00149-0","article-title":"Regenerative therapy for spinal cord injury using iPSC technology.","volume":"40","author":"Nagoshi","year":"2020","journal-title":"Inflamm. Regen."},{"key":"B169","doi-asserted-by":"publisher","first-page":"126","DOI":"10.4252\/wjsc.v7.i1.126","article-title":"Adult human neural stem cell therapeutics: current developmental status and prospect.","volume":"7","author":"Nam","year":"2015","journal-title":"World J. Stem Cells"},{"key":"B170","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S1474-4422(04)00770-7","article-title":"Are statins a treatment option for multiple sclerosis?","volume":"3","author":"Neuhaus","year":"2004","journal-title":"Lancet Neurol."},{"key":"B171","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.stem.2019.08.015","article-title":"Metformin restores CNS remyelination capacity by rejuvenating aged stem cells.","volume":"25","author":"Neumann","year":"2019","journal-title":"Cell Stem Cell"},{"key":"B172","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.expneurol.2016.11.012","article-title":"iPS-derived neural progenitor cells from PPMS patients reveal defect in myelin injury response.","volume":"288","author":"Nicaise","year":"2017","journal-title":"Exp. Neurol."},{"key":"B173","doi-asserted-by":"publisher","first-page":"9030","DOI":"10.1073\/pnas.1818348116","article-title":"Cellular senescence in progenitor cells contributes to diminished remyelination potential in progressive multiple sclerosis.","volume":"116","author":"Nicaise","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B174","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/nrm3049","article-title":"The elusive nature and function of mesenchymal stem cells.","volume":"12","author":"Nombela-Arrieta","year":"2011","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B175","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/nm837","article-title":"Identification and isolation of multipotential neural progenitor cells from the subcortical white matter of the adult human brain.","volume":"9","author":"Nunes","year":"2003","journal-title":"Nat. Med."},{"key":"B176","doi-asserted-by":"publisher","first-page":"783","DOI":"10.3892\/ijmm.2017.3298","article-title":"Comparative analysis of human embryonic stem cell-derived neural stem cells as an in vitro human model.","volume":"41","author":"Oh","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101860","article-title":"Growing evidence supporting the use of mesenchymal stem cell therapies in multiple sclerosis: a systematic review.","volume":"38","author":"Oliveira","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"B178","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.htct.2020.03.002","article-title":"A review of hematopoietic stem cell transplantation for autoimmune diseases: multiple sclerosis, systemic sclerosis and Crohn\u2019s disease. Position paper of the Brazilian Society of Bone Marrow Transplantation.","volume":"43","author":"Oliveira","year":"2021","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"B179","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1177\/1352458517729465","article-title":"Clinical outcome measures for progressive MS trials.","volume":"23","author":"Ontaneda","year":"2017","journal-title":"Mult. Scler. J."},{"key":"B180","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s00109-018-1686-x","article-title":"Targeting senescence to delay progression of multiple sclerosis.","volume":"96","author":"Oost","year":"2018","journal-title":"J. Mol. Med."},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20246305","article-title":"The challenge of bringing iPSCs to the patient.","volume":"20","author":"Ortu\u00f1o-Costela","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B182","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1212\/01.wnl.0000146958.77317.3e","article-title":"Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.","volume":"63","author":"Panitch","year":"2004","journal-title":"Neurology"},{"key":"B183","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.stem.2018.01.020","article-title":"Macrophage-derived extracellular succinate licenses neural stem cells to suppress chronic neuroinflammation.","volume":"22","author":"Peruzzotti-Jametti","year":"2018","journal-title":"Cell Stem Cell"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3001166","article-title":"Neural stem cells traffic functional mitochondria via extracellular vesicles.","volume":"19","author":"Peruzzotti-Jametti","year":"2021","journal-title":"PLoS Biol."},{"key":"B185","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.molmed.2018.07.007","article-title":"Targeting mitochondrial metabolism in neuroinflammation: towards a therapy for progressive multiple sclerosis.","volume":"24","author":"Peruzzotti-Jametti","year":"2018","journal-title":"Trends Mol. Med."},{"key":"B186","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1093\/brain\/awaa333","article-title":"Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis.","volume":"143","author":"Petrou","year":"2020","journal-title":"Brain"},{"key":"B187","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.stem.2015.01.004","article-title":"Human embryonic stem cell-derived oligodendrocyte progenitors remyelinate the brain and rescue behavioral deficits following radiation.","volume":"16","author":"Piao","year":"2015","journal-title":"Cell Stem Cell"},{"key":"B188","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1002\/glia.22500","article-title":"How stem cells speak with host immune cells in inflammatory brain diseases.","volume":"61","author":"Pluchino","year":"2013","journal-title":"Glia"},{"key":"B189","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/ana.21745","article-title":"Human neural stem cells ameliorate autoimmune encephalomyelitis in non-human primates.","volume":"66","author":"Pluchino","year":"2009","journal-title":"Ann. Neurol."},{"key":"B190","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/nature01552","article-title":"Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis.","volume":"422","author":"Pluchino","year":"2003","journal-title":"Nature"},{"key":"B191","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.molmed.2020.04.005","article-title":"Promises and limitations of neural stem cell therapies for progressive multiple sclerosis.","volume":"26","author":"Pluchino","year":"2020","journal-title":"Trends Mol. Med."},{"key":"B192","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/nature03889","article-title":"Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism.","volume":"436","author":"Pluchino","year":"2005","journal-title":"Nature"},{"key":"B193","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ejphar.2015.03.042","article-title":"Animal models of multiple sclerosis.","volume":"759","author":"Procaccini","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"B194","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1007\/s13311-020-00847-0","article-title":"Induction versus escalation in multiple sclerosis: a 10-year real world study.","volume":"17","author":"Prosperini","year":"2020","journal-title":"Neurotherapeutics"},{"key":"B195","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/j.1365-2141.2005.05409.x","article-title":"Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells.","volume":"129","author":"Puissant","year":"2005","journal-title":"Br. J. Haematol."},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013049.pub2","article-title":"Stem cell therapy for multiple sclerosis.","volume":"2019","author":"Rahim","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"B197","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/01.tp.0000244572.24780.54","article-title":"Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle.","volume":"83","author":"Ramasamy","year":"2007","journal-title":"Transplantation"},{"key":"B198","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple sclerosis.","volume":"378","author":"Reich","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B199","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1126\/science.1553558","article-title":"Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system.","volume":"255","author":"Reynolds","year":"1992","journal-title":"Science"},{"key":"B200","doi-asserted-by":"publisher","first-page":"6670","DOI":"10.1021\/acsnano.9b01004","article-title":"Stem cell-derived exosomes as nanotherapeutics for autoimmune and neurodegenerative disorders.","volume":"13","author":"Riazifar","year":"2019","journal-title":"ACS Nano"},{"key":"B201","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1146\/annurev-pharmtox-061616-030146","article-title":"Stem cell extracellular vesicles: extended messages of regeneration.","volume":"57","author":"Riazifar","year":"2017","journal-title":"Annu. Rev. Pharmacol. Tox."},{"key":"B202","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1212\/wnl.54.5.1145","article-title":"Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI study group.","volume":"54","author":"Rice","year":"2000","journal-title":"Neurology"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-018-1433-7","article-title":"Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis.","volume":"16","author":"Riordan","year":"2018","journal-title":"J. Transl. Med."},{"key":"B204","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1093\/brain\/awaa231","article-title":"Delay from treatment start to full effect of immunotherapies for multiple sclerosis.","volume":"143","author":"Roos","year":"2020","journal-title":"Brain"},{"key":"B205","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/nm.4106","article-title":"Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor.","volume":"22","author":"Rothhammer","year":"2016","journal-title":"Nat. Med."},{"key":"B206","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1080\/08820139.2018.1504301","article-title":"Therapeutic use of intrathecal mesenchymal stem cells in patients with multiple sclerosis: a pilot study with booster injection.","volume":"48","author":"Sahraian","year":"2019","journal-title":"Immunol. Invest."},{"key":"B207","doi-asserted-by":"publisher","first-page":"5693","DOI":"10.4049\/jimmunol.1002188","article-title":"Contribution of astrocyte-derived IL-15 to CD8 T cell effector functions in multiple sclerosis.","volume":"185","author":"Saikali","year":"2010","journal-title":"J. Immunol."},{"key":"B208","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1177\/1352458516634871","article-title":"Aging and multiple sclerosis.","volume":"22","author":"Sanai","year":"2016","journal-title":"Mult. Scler. J."},{"key":"B209","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1177\/1352458516630396","article-title":"The relationship of age with the clinical phenotype in multiple sclerosis.","volume":"22","author":"Scalfari","year":"2016","journal-title":"Mult. Scler. J."},{"key":"B210","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1136\/jnnp-2012-304333","article-title":"Onset of secondary progressive phase and long-term evolution of multiple sclerosis.","volume":"85","author":"Scalfari","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B211","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1093\/brain\/awx154","article-title":"Cell-based therapeutic strategies for multiple sclerosis.","volume":"140","author":"Scolding","year":"2017","journal-title":"Brain"},{"key":"B212","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.msard.2015.01.005","article-title":"High doses of biotin in chronic progressive multiple sclerosis: a pilot study.","volume":"4","author":"Sedel","year":"2015","journal-title":"Mult. Scler. Relat. Disord."},{"key":"B213","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1634\/stemcells.2007-0554","article-title":"Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells.","volume":"26","author":"Selmani","year":"2008","journal-title":"Stem Cells"},{"key":"B214","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1750-3639.2004.tb00049.x","article-title":"Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis.","volume":"14","author":"Serafini","year":"2004","journal-title":"Brain Pathol."},{"key":"B215","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1111\/trf.12421","article-title":"Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices.","volume":"54","author":"Sharma","year":"2014","journal-title":"Transfusion"},{"key":"B216","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41409-019-0684-0","article-title":"Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT autoimmune diseases working party (ADWP) and the joint accreditation committee of EBMT and ISCT (JACIE).","volume":"55","author":"Sharrack","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"B217","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/glia.10053","article-title":"Hyaluronate-based extracellular matrix: keeping glia in their place.","volume":"38","author":"Sherman","year":"2002","journal-title":"Glia"},{"key":"B218","doi-asserted-by":"publisher","first-page":"944","DOI":"10.12659\/ajcr.899745","article-title":"Transplantation of human embryonic stem cells in patients with multiple sclerosis and lyme disease.","volume":"17","author":"Shroff","year":"2016","journal-title":"Am. J. Case Rep."},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/5762916","article-title":"Adipose-derived cells (stromal vascular fraction) transplanted for orthopedical or neurological purposes: are they safe enough?","volume":"2016","author":"Siennicka","year":"2016","journal-title":"Stem Cells Int."},{"key":"B220","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/s0022-510x(96)00224-9","article-title":"High resolution proton MR spectroscopy of cerebrospinal fluid in MS patients. Comparison with biochemical changes in demyelinating plaques.","volume":"144","author":"Simone","year":"1996","journal-title":"J. Neurol. Sci."},{"key":"B221","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1089\/scd.2017.0009","article-title":"Human neural stem cell therapy for chronic ischemic stroke: charting progress from laboratory to patients.","volume":"26","author":"Sinden","year":"2017","journal-title":"Stem Cells Dev."},{"key":"B222","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/B978-0-12-818084-6.00006-4","article-title":"The therapeutic potential of exogenous adult stem cells for the injured central nervous system","author":"Smith","year":"2020","journal-title":"Handbook of Innovations in Central Nervous System Regenerative Medicine"},{"key":"B223","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1182\/bloodadvances.2017010041","article-title":"Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases.","volume":"1","author":"Snowden","year":"2017","journal-title":"Blood Adv."},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000374","article-title":"Lipoic acid in secondary progressive MS: a randomized controlled pilot trial.","volume":"4","author":"Spain","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"B225","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3727\/096368915x689622","article-title":"Clinical trials with mesenchymal stem cells: an update.","volume":"25","author":"Squillaro","year":"2016","journal-title":"Cell Transplant."},{"key":"B226","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S1474-4422(18)30498-8","article-title":"A global perspective on the burden of multiple sclerosis.","volume":"18","author":"Stenager","year":"2019","journal-title":"Lancet Neurol."},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/5302120","article-title":"Clinical application of autologous adipose stem cells in patients with multiple sclerosis: preliminary results.","volume":"2016","author":"Stepien","year":"2016","journal-title":"Mediators Inflamm."},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.3389\/fnhum.2018.00226","article-title":"Metabolomic profiles for primary progressive multiple sclerosis stratification and disease course monitoring.","volume":"12","author":"Stoessel","year":"2018","journal-title":"Front. Hum. Neurosci."},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-020-00960-3","article-title":"Transplantation of induced neural stem cells (iNSCs) into chronically demyelinated corpus callosum ameliorates motor deficits.","volume":"8","author":"Sullivan","year":"2020","journal-title":"Acta Neuropathol. Commun."},{"key":"B230","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","article-title":"Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors.","volume":"126","author":"Takahashi","year":"2006","journal-title":"Cell"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.504","article-title":"Current progress in the derivation and therapeutic application of neural stem cells.","volume":"8","author":"Tang","year":"2017","journal-title":"Cell Death Dis."},{"key":"B232","doi-asserted-by":"publisher","first-page":"9185","DOI":"10.1002\/jcp.29803","article-title":"Mesenchymal stromal cells; a new horizon in regenerative medicine.","volume":"235","author":"Tavakoli","year":"2020","journal-title":"J. Cell. Physiol."},{"key":"B233","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1196\/annals.1361.066","article-title":"Premature immunosenescence in rheumatoid arthritis and multiple sclerosis patients.","volume":"1051","author":"Thewissen","year":"2005","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"B234","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.stem.2012.03.003","article-title":"Direct conversion of fibroblasts into stably expandable neural stem cells.","volume":"10","author":"Thier","year":"2012","journal-title":"Cell Stem Cell"},{"key":"B235","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.5966\/sctm.2016-0024","article-title":"Survival and functionality of human induced pluripotent stem cell-derived oligodendrocytes in a nonhuman primate model for multiple sclerosis.","volume":"5","author":"Thiruvalluvan","year":"2016","journal-title":"Stem Cells Transl. Med."},{"key":"B236","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-019-0864-6","article-title":"Polarizing receptor activation dissociates fibroblast growth factor 2 mediated inhibition of myelination from its neuroprotective potential.","volume":"7","author":"Th\u00fcmmler","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"B237","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/glia.21088","article-title":"Inhibition of reactive astrocytosis in established experimental autoimmune encephalomyelitis favors infiltration by myeloid cells over T cells and enhances severity of disease.","volume":"59","author":"Toft-Hansen","year":"2011","journal-title":"Glia"},{"key":"B238","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1177\/1352458516667568","article-title":"MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: a randomised, double-blind, placebo-controlled study.","volume":"22","author":"Tourbah","year":"2016","journal-title":"Mult. Scler. J."},{"key":"B239","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1212\/WNL.0000000000001744","article-title":"Mitochondrial DNA sequence variation in multiple sclerosis.","volume":"85","author":"Tranah","year":"2015","journal-title":"Neurology"},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-019-3346-z","article-title":"MEsenchymal StEm cells for multiple sclerosis (MESEMS): a randomized, double blind, cross-over phase I\/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis.","volume":"20","author":"Uccelli","year":"2019","journal-title":"Trials"},{"key":"B241","article-title":"MEsenchymal StEm cells for multiple sclerosis (MESEMS) study: results from a multi-center, randomized, double blind, cross-over phase 2 clinical trial with autologous mesenchymal stem cells (MSC) for the therapy of multiple sclerosis.","author":"Uccelli","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"B242","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.beha.2004.04.003","article-title":"Stem cell transplantation for autoimmune disorders. Preclinical experiments.","volume":"17","author":"van Bekkum","year":"2004","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"B243","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/stem.140460","article-title":"Severe autoimmune diseases: a new target for bone marrow transplantation.","volume":"14","author":"van Bekkum","year":"1996","journal-title":"Stem Cells"},{"key":"B244","first-page":"233","article-title":"Treatment of experimental allergic encephalomyelitis in rats with total body irradiation and syngeneic BMT.","volume":"11","author":"van Gelder","year":"1993","journal-title":"Bone Marrow Transplant."},{"key":"B245","first-page":"343","article-title":"Treatment of relapsing experimental autoimmune encephalomyelitis in rats with allogeneic bone marrow transplantation from a resistant strain.","volume":"16","author":"van Gelder","year":"1995","journal-title":"Bone Marrow Transplant."},{"key":"B246","first-page":"1029","article-title":"Effective treatment of relapsing experimental autoimmune encephalomyelitis with pseudoautologous bone marrow transplantation.","volume":"18","author":"van Gelder","year":"1996","journal-title":"Bone Marrow Transplant."},{"key":"B247","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nrm.2017.125","article-title":"Shedding light on the cell biology of extracellular vesicles.","volume":"19","author":"van Niel","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B248","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jneuroim.2008.04.030","article-title":"Autologous and allogeneic hematopoietic stem cell transplantation for multiple sclerosis: perspective on mechanisms of action.","volume":"197","author":"Van Wijmeersch","year":"2008","journal-title":"J. Neuroimmunol."},{"key":"B249","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000321","article-title":"Metabolomic signatures associated with disease severity in multiple sclerosis.","volume":"4","author":"Villoslada","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"B250","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.ebiom.2018.11.026","article-title":"Neural stem cell derived extracellular vesicles: attributes and prospects for treating neurodegenerative disorders.","volume":"38","author":"Vogel","year":"2018","journal-title":"EBioMedicine"},{"key":"B251","doi-asserted-by":"publisher","first-page":"36","DOI":"10.7150\/ijms.21666","article-title":"Ethical and safety issues of stem cell-based therapy.","volume":"15","author":"Volarevic","year":"2018","journal-title":"Int. J. Med. Sci."},{"key":"B252","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1161\/strokeaha.107.502047","article-title":"Dual-modality monitoring of targeted intraarterial delivery of mesenchymal stem cells after transient ischemia.","volume":"39","author":"Walczak","year":"2008","journal-title":"Stroke"},{"key":"B253","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.expneurol.2008.11.017","article-title":"Neural stem\/progenitor cells modulate immune responses by suppressing T lymphocytes with nitric oxide and prostaglandin E2.","volume":"216","author":"Wang","year":"2009","journal-title":"Exp. Neurol."},{"key":"B254","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.3892\/etm.2017.4423","article-title":"Safety of neural stem cell transplantation in patients with severe traumatic brain injury.","volume":"13","author":"Wang","year":"2017","journal-title":"Exp. Ther. Med."},{"key":"B255","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/aps.2013.50","article-title":"Mesenchymal stem cells: a new trend for cell therapy.","volume":"34","author":"Wei","year":"2013","journal-title":"Acta Pharmacol. Sin."},{"key":"B256","doi-asserted-by":"publisher","first-page":"176","DOI":"10.4103\/2468-5658.196984","article-title":"Neurologic Stem Cell Treatment Study (NEST) using bone marrow derived stem cells for the treatment of neurological disorders and injuries: study protocol for a nonrandomized efficacy trial.","volume":"1","author":"Weiss","year":"2016","journal-title":"Clin. Trials Degen. Dis."},{"key":"B257","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav8521","article-title":"Advances in therapeutic applications of extracellular vesicles.","volume":"11","author":"Wiklander","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"B258","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2019.146615","article-title":"The neural stem cell secretome and its role in brain repair.","volume":"1729","author":"Willis","year":"2020","journal-title":"Brain Res."},{"key":"B259","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/ana.21079","article-title":"Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial.","volume":"61","author":"Wolinsky","year":"2007","journal-title":"Ann. Neurol."},{"key":"B260","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.it.2015.11.005","article-title":"Understanding stem cell immunogenicity in therapeutic applications.","volume":"37","author":"Wood","year":"2016","journal-title":"Trends Immunol."},{"key":"B261","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-020-01855-9","article-title":"Mesenchymal stromal cell therapies: immunomodulatory properties and clinical progress.","volume":"11","author":"Wu","year":"2020","journal-title":"Stem Cell Res. Ther."},{"key":"B262","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2021.102022","article-title":"Role of extracellular vesicles in neurodegenerative diseases.","volume":"201","author":"Xiao","year":"2021","journal-title":"Prog. Neurobiol."},{"key":"B263","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2174\/1574888x10666150302110013","article-title":"Induced stem cells as a novel multiple sclerosis therapy.","volume":"11","author":"Xie","year":"2016","journal-title":"Curr. Stem Cell Res. Ther."},{"key":"B264","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.imlet.2020.05.005","article-title":"Changes of immune parameters of T lymphocytes and macrophages in EAE mice after BM-MSCs transplantation.","volume":"225","author":"Xin","year":"2020","journal-title":"Immunol. Lett."},{"key":"B265","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jneuroim.2010.07.013","article-title":"Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study.","volume":"227","author":"Yamout","year":"2010","journal-title":"J. Neuroimmunol."},{"key":"B266","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1634\/stemcells.2006-0228","article-title":"Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease.","volume":"24","author":"Yanez","year":"2006","journal-title":"Stem Cells"},{"key":"B267","doi-asserted-by":"publisher","first-page":"3678","DOI":"10.1172\/JCI37914","article-title":"Adult neural stem cells expressing IL-10 confer potent immunomodulation and remyelination in experimental autoimmune encephalitis.","volume":"119","author":"Yang","year":"2009","journal-title":"J. Clin. Invest."},{"key":"B268","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/s41586-018-0842-3","article-title":"Dynamics of oligodendrocyte generation in multiple sclerosis.","volume":"566","author":"Yeung","year":"2019","journal-title":"Nature"},{"key":"B269","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.bbi.2019.05.029","article-title":"Astrocytes in multiple sclerosis and experimental autoimmune encephalomyelitis: star-shaped cells illuminating the darkness of CNS autoimmunity.","volume":"80","author":"Yi","year":"2019","journal-title":"Brain Behav. Immun."},{"key":"B270","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jneuroim.2018.11.015","article-title":"Various strategies to improve efficacy of stem cell transplantation in multiple sclerosis: focus on mesenchymal stem cells and neuroprotection.","volume":"328","author":"Yousefi","year":"2019","journal-title":"J. Neuroimmunol."},{"key":"B271","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41586-021-03547-7","article-title":"An aged immune system drives senescence and ageing of solid organs.","volume":"594","author":"Yousefzadeh","year":"2021","journal-title":"Nature"},{"key":"B272","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1126\/science.1151526","article-title":"Induced pluripotent stem cell lines derived from human somatic cells.","volume":"318","author":"Yu","year":"2007","journal-title":"Science"},{"key":"B273","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1182\/blood-2005-04-1496","article-title":"Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy.","volume":"106","author":"Zappia","year":"2005","journal-title":"Blood"},{"key":"B274","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1007\/s11427-016-0114-9","article-title":"Treatment of multiple sclerosis by transplantation of neural stem cells derived from induced pluripotent stem cells.","volume":"59","author":"Zhang","year":"2016","journal-title":"Sci. China Life Sci."},{"key":"B275","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/sctm.18-0220","article-title":"Stable intracerebral transplantation of neural stem cells for the treatment of paralysis due to ischemic stroke.","volume":"8","author":"Zhang","year":"2019","journal-title":"Stem Cells Transl. Med."},{"key":"B276","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/nature10135","article-title":"Immunogenicity of induced pluripotent stem cells.","volume":"474","author":"Zhao","year":"2011","journal-title":"Nature"},{"key":"B277","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00441-017-2738-1","article-title":"Neural stem cells: developmental mechanisms and disease modeling.","volume":"371","author":"Zhao","year":"2018","journal-title":"Cell Tissue Res."},{"key":"B278","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.4049\/jimmunol.1003307","article-title":"IL-9 promotes Th17 cell migration into the central nervous system via CC chemokine ligand-20 produced by astrocytes.","volume":"186","author":"Zhou","year":"2011","journal-title":"J. Immunol."},{"key":"B279","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1136\/jnnp-2020-323992","article-title":"Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing\u2013remitting multiple sclerosis: an observational study.","volume":"92","author":"Zhukovsky","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2021.696434\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T13:27:18Z","timestamp":1672752438000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2021.696434\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,9]]},"references-count":279,"alternative-id":["10.3389\/fcell.2021.696434"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2021.696434","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,9]]},"article-number":"696434"}}